trustpilot Fantastic service
Great service with regard to both information…
logomysorgente

02  4948  5291

  • What is AURORA

    Aurora is a next-generation noninvasive prenatal test. AURORA is safe, reliable, quick
    and early

  • Safe

    Thanks to an easy maternal blood drawn, you avoid miscarriage risks associated to invasive methods such as amniocentesis or chorionic villus sampling

  • Reliable

    Sensitivity higher than 99,9% for detecting the trisomy 21, responsible for the Down syndrome

  • Early and quick

    icona svegliaThe early detection of chromosome abnormalities is foundamental:
    you can undergo AURORA from the 10th week of pregnancy

    icona documentoThe test is quick: results are available in 5-7 working days. AURORA has the lower percentage of null test of the market: 0,1%

  • Mother's serenity in three simple steps

    icotelefona

    BOOK THE TEST

    icoesami

    MAKE A PERIPHERAL BLOOD DRAW

    icoginecologo

    READ RESULTS

  • eng slide mobile01
  • eng 2 151126 banner Aurora mobile 01
  • eng 151126 banner Aurora mobile 02
  • eng 151126 banner Aurora mobile 03
  • eng slide mobile05
Eng cover cartoon
Eng cover venturetti

Latest news from the world of genetics


New genetic test to diagnose hereditary angioedema

A new genetic test could make the diagnosis of hereditary angioedema easier. The test analyzes all the SERPING1 gene. According to the study published in the journal Gene, the new method identifies types 1 and 2 of the disease much better than traditional tests. For this reason, researchers recommend its use alongside traditional diagnostic methods.

Hereditary angioedema is a rare genetic disease that causes cutaneous and subcutaneous swelling. Type 1 angioedema is caused by low levels of the C1 protein, while type 2 is linked to a defective protein. Type 3 is the result of some mutations in the coagulant factor XII.
In the new study, researchers analyzed the DNA of a group of subjects possibly suffering from angioedema. The aim was to give a more precise diagnosis and to better understand the nature of the disease. Tests reported more than 450 mutations in the SERPING1 gene. The gene provides instructions for making the C1 inhibitor protein.

Genetic tests usually used for the diagnosis of the disease are long and unreliable. In 5-10% of cases they are not even able to detect SERPING1 mutations. In fact, traditional genetic tests do not cover the whole gene and skip regions that are not translated into proteins. Unfortunately, mutations may also be present in these regions. The new test then also analyzes the parts of the gene previously ignored.

The study authors validated the new test using 102 samples of DNA analyzed by traditional methods. They also used 115 samples with negative results and 95 samples taken from relatives of the patients. The new test identified the mutation at SERPING1 in 91 patients already diagnosed, but on which the traditional tests had not worked. Furthermore, they identified 15 entirely new mutations.
According to the study, the new genetic test is 98.96% reliable and has an accuracy of 99.35%. The false negative rate was very low.

Source: angioedemanews.com

Link social

Link social